Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for obesity and related metabolic conditions. Kailera Therapeutics advances a diversified pipeline of injectable and oral product candidates built around GLP-1-based mechanisms, including programs that target GLP-1, GIP, and glucagon pathways. Its portfolio is designed to address different patient needs in obesity care through multiple routes of administration and varying dosing approaches. The company’s lead program, ribupatide, is a once-weekly injectable GLP-1/GIP dual agonist being evaluated in late-stage clinical development. Kailera Therapeutics also works on oral small-molecule and peptide candidates that expand its treatment options across the weight-management market. Based in Waltham, Massachusetts, Kailera Therapeutics serves the biotechnology and metabolic disease sectors with a focus on modern obesity care.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Ronald C. Renaud Jr., M.B.A.

Employees

145

Headquarters

Waltham, MA, United States

Website

www.kailera.com